AMP® Symposium Day 2: Bespoke Gene Therapy Consortium
The Accelerating Medicines Partnership® (AMP®) Program Bespoke Gene Therapy Consortium (AMP BGTC) brings together partners from the public, private, and non-profit sectors to foster development of gene therapies intended to treat rare genetic diseases, which affect populations too small for viable commercial development.
Building on the successful AMP model, this program focuses on generating a standard operational playbook for developing such gene therapies. This playbook, which will be established and piloted using up to eight clinical trial test cases, will include streamlined templates, master regulatory files, and uniform manufacturing processes to create a pathway toward the commercial viability and sustainability of gene therapies for very rare diseases. This approach could have substantial positive impacts on the larger gene therapy field, especially as the field moves into the era of genome editing.
The Accelerating Medicines Partnership® (AMP®) Program was launched in February 2014 to bring together the resources and expertise of both the National Institutes of Health (NIH) and the private sector to solve pressing challenges in various diseases and disease areas. The AMP program, managed by the FNIH, is comprised of projects with a common goal of accelerating the process of bringing new and effective therapies to patients and operates under the broad principle of delivering pre-competitive advancements to the research and medical fields to enable broad access and use of AMP research discoveries. Originally focused on three specific diseases, the program has since grown to 10 individual projects representing the contributions and participation of 16 NIH institutes and over 70 private sector partners.
This inaugural scientific symposium celebrated the 10th anniversary of the program, highlighted successful innovation and collaboration in each of the individual AMP project areas, and provided a forum for discussions and cross-collaboration in the broader AMP research community.
https://fnih.org/our-programs/accelerating-medicines-partnership-amp/bespoke-gene-therapy-consortium-bgtc/
Видео AMP® Symposium Day 2: Bespoke Gene Therapy Consortium канала FNIH
Building on the successful AMP model, this program focuses on generating a standard operational playbook for developing such gene therapies. This playbook, which will be established and piloted using up to eight clinical trial test cases, will include streamlined templates, master regulatory files, and uniform manufacturing processes to create a pathway toward the commercial viability and sustainability of gene therapies for very rare diseases. This approach could have substantial positive impacts on the larger gene therapy field, especially as the field moves into the era of genome editing.
The Accelerating Medicines Partnership® (AMP®) Program was launched in February 2014 to bring together the resources and expertise of both the National Institutes of Health (NIH) and the private sector to solve pressing challenges in various diseases and disease areas. The AMP program, managed by the FNIH, is comprised of projects with a common goal of accelerating the process of bringing new and effective therapies to patients and operates under the broad principle of delivering pre-competitive advancements to the research and medical fields to enable broad access and use of AMP research discoveries. Originally focused on three specific diseases, the program has since grown to 10 individual projects representing the contributions and participation of 16 NIH institutes and over 70 private sector partners.
This inaugural scientific symposium celebrated the 10th anniversary of the program, highlighted successful innovation and collaboration in each of the individual AMP project areas, and provided a forum for discussions and cross-collaboration in the broader AMP research community.
https://fnih.org/our-programs/accelerating-medicines-partnership-amp/bespoke-gene-therapy-consortium-bgtc/
Видео AMP® Symposium Day 2: Bespoke Gene Therapy Consortium канала FNIH
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
FNIH highlights success of the ABC-CT program in advancing neuropsychiatric biomarkers for autism2015 Year in ReviewDr Ruslan M Medzhitov Wins 2013 Lurie Prize in Biomedical SciencesAccelerating Medicines Partnership - Alzheimer's DiseaseDr. Jeannie T. Lee's Scientific Research in Epigenetic RegulationNBC 4 Report: I-SPY 2 Clinical TrialExpert Talk with 2022 Lurie Prize recipients Anne Brunet, PhD, and Andrew Dillin, PhDEffector Function Seminar Series: Mouse models of effector function/FcR & IgG allotype polymorphismsVision for AMP HF - Dr. Sanjiv ShahAbout 2021 Lurie Prize Recipient Dr. Xiaowei ZhuangCharles A. Sanders, M.D., Scientific SymposiumEffector Function Seminar Series: Convalescent plasma correlates of protectionThe 22nd Annual Norman P. Salzman Memorial Awards and Symposium in Basic and Clinical VirologyFNIH AMP RA/Lupus Patient PerspectiveExpert Talk with Dr. Xiaowei ZhuangNon-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)The Quiet Leaders of COVID: Shaping The Future Of Science2020 Lurie Prize Recipient Aviv Regev, Ph.D. Research07_Beyond P-Values_ Computing the Probability of a True Association06_An Empirical Approach to Null Hypothesis Testing2019 FNIH Biomarkers Consortium Neuroscience Symposium Session 3 - Imaging Biomarkers